In Q2 2026, Corcept Therapeutics reported accelerated revenue growth driven primarily by its established Hypercortisolism Products and the first full quarter contribution from Lifyorli, approved in early 2026 for platinum-resistant ovarian cancer. Corcept leverages a focused business model centered on selective cortisol modulators to treat endocrine disorders and certain cancers, combining patented compounds with targeted commercialization through specialty pharmacies. The company’s competitive positioning benefits from FDA approvals and exclusivity but faces typical biotech risks such as regulatory hurdles and reimbursement pressure. Its financial profile shows strong liquidity supporting ongoing research and patient access programs. Key near-term growth drivers include expanding Lifyorli market penetration and advancing additional compounds in its development pipeline.